{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:46:39Z","timestamp":1776577599991,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.111040","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:07:16Z","timestamp":1772327236000},"page":"111040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is More Better? Evaluating Neoadjuvant Chemotherapy Cycles Before Surgery for High-Risk Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-9293","authenticated-orcid":false,"given":"Taibo","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Br\u00f6nimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Cheaib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surena F","family":"Matin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M","family":"Potretzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannie","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.111040_bib0001","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1464-410X.2012.11066.x","article-title":"Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients","volume":"110","author":"Grasso","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.111040_bib0002","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma","volume":"4","author":"Coll\u00e0 Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0003","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.urolonc.2016.11.018","article-title":"Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma","volume":"35","author":"Cohen","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0004","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.111040_bib0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bju.12597","article-title":"Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"114","author":"Kaag","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.111040_bib0006","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/cncr.25043","article-title":"Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy","volume":"116","author":"Lane","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.111040_bib0007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","article-title":"Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy","volume":"58","author":"Kaag","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0008","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2019.01.058","article-title":"High response rates to neoadjuvant chemotherapy in High-grade upper tract urothelial carcinoma","volume":"129","author":"Meng","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.111040_bib0009","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.clgc.2020.10.001","article-title":"Neoadjuvant versus Adjuvant chemotherapy for upper tract urothelial carcinoma: a microsimulation model","volume":"19","author":"Hird","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.111040_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2017.12.054","article-title":"Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma","volume":"200","author":"Liao","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0011","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1016\/j.clgc.2018.08.003","article-title":"Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery","volume":"16","author":"Almassi","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.111040_bib0012","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clgc.2021.12.014","article-title":"Five and ten-year outcomes of neoadjuvant chemotherapy and surgery for high-risk upper tract urothelial carcinoma","volume":"20","author":"Adibi","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.111040_bib0013","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","article-title":"Multicenter phase II clinical trial of Gemcitabine and Cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma","volume":"41","author":"Coleman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0014","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0015","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.urolonc.2024.11.025","article-title":"The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: results from the upper tract collaborative network (UCAN)","volume":"43","author":"Carpinito","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0016","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0017","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0018","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.urolonc.2024.11.025","article-title":"The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: results from the upper tract collaborative network (UCAN)","volume":"43","author":"Carpinito","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040793","article-title":"Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts","volume":"20","author":"Tse","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.111040_bib0020","doi-asserted-by":"crossref","first-page":"933.e7","DOI":"10.1016\/j.urolonc.2020.04.025","article-title":"Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma","volume":"38","author":"Singla","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0021","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.euo.2024.01.010","article-title":"Oncologic outcomes in patients with residual upper tract urothelial carcinoma following neoadjuvant chemotherapy","volume":"7","author":"Fletcher","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0022","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and Adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and Future perspectives on Systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0023","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.euf.2017.03.013","article-title":"Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma","volume":"4","author":"Hosogoe","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.111040_bib0024","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bju.15230","article-title":"Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma","volume":"127","author":"Zennami","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.111040_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JU.0000000000002189","article-title":"Four versus 3 cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: implications for pathological response and survival","volume":"207","author":"Patel","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0026","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/JU.0000000000002190","article-title":"Identifying the optimal number of neoadjuvant chemotherapy cycles in patients with muscle invasive bladder cancer","volume":"207","author":"D\u2019Andrea","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0027","doi-asserted-by":"crossref","first-page":"453.e19","DOI":"10.1016\/j.urolonc.2022.05.023","article-title":"Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer","volume":"40","author":"Aydin","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2281654","article-title":"Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"55","author":"Wang","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.urolonc.2026.111040_bib0029","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bju.16319","article-title":"The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer","volume":"134","author":"von Deimling","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.111040_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70782","article-title":"Effects of the number of neoadjuvant cycles and addition of adjuvant chemotherapy on the prognosis of muscle-invasive bladder cancer treated with radical cystectomy","volume":"14","author":"Hatakeyama","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.111040_bib0031","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.urolonc.2010.04.002","article-title":"Upper tract urothelial carcinoma: impact of time to surgery","volume":"30","author":"Sundi","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11144007","article-title":"The impact of surgical waiting time on oncological outcomes in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy: a systematic review","volume":"11","author":"Nowak","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2026.111040_bib0033","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/iju.15362","article-title":"Summary of the Clinical Practice Guidelines for upper tract urothelial carcinoma 2023 by the Japanese Urological Association","volume":"31","author":"Mori","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.111040_bib0036","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00262-024-03910-3","article-title":"Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis","volume":"74","author":"Yanagisawa","year":"2025","journal-title":"Cancer Immunol Immunother"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:18:02Z","timestamp":1776575882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1078143926000517"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111040","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is More Better? Evaluating Neoadjuvant Chemotherapy Cycles Before Surgery for High-Risk Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111040"}}